Company intelligence / Profile preview

Eco-Fusion

Tel Aviv or Herzliya [conflicting sources list both], Israelecofusion.net ↗

Ownership: Private
Development stage: Commercial

Overview

Eco-Fusion’s Serenita platform has been clinically shown to reduce blood sugar in Type II diabetics by managing stress through AI-driven personalized digital therapeutics. The company integrates wearables, mobile apps, gaming, and social interaction to support healthy lifestyle changes

Therapeutic areas: PsychiatryEndocrinology
Modalities: Digital therapeuticMobile applicationWearable-integrated therapy
Industry: Digital Health Medical Devices

Beyond the preview

Go deeper on Eco-Fusion.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eco-Fusion.

Explore the full profile